Literature DB >> 28627311

Landmark cure rate models with time-dependent covariates.

Haolun Shi1, Guosheng Yin1.   

Abstract

We propose a class of landmark cure rate models by incorporating time-dependent covariates. The landmark approach enables us to obtain dynamic predictions of a patient's survival probabilities as new clinical information emerges during the follow-up time. The proposed method extends the landmark model for failure time data with a possible cure fraction. We specify a series of landmark time points, and for each of time point, we construct a landmark data set consisting of only those at-risk individuals at the landmark time. The time-dependent covariates can be fixed at the values evaluated at the landmark time point. Through landmarking, our framework accommodates the Cox proportional hazards model, accelerated failure time model and censored quantile regression model in the presence of a cure proportion. We conduct simulation studies to assess the estimation accuracy of the proposed method, and illustrate it with data from a heart transplant study.

Entities:  

Keywords:  Cure rate model; dynamic prediction; landmark analysis; proportional hazards model; survival fraction

Mesh:

Year:  2017        PMID: 28627311     DOI: 10.1177/0962280217708681

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  4 in total

1.  Improved Landmark Dynamic Prediction Model to Assess Cardiovascular Disease Risk in On-Treatment Blood Pressure Patients: A Simulation Study and Post Hoc Analysis on SPRINT Data.

Authors:  Mehrab Sayadi; Najaf Zare; Armin Attar; Seyyed Mohammad Taghi Ayatollahi
Journal:  Biomed Res Int       Date:  2020-04-22       Impact factor: 3.411

2.  A comparison of the beta-geometric model with landmarking for dynamic prediction of time to pregnancy.

Authors:  Rik van Eekelen; Hein Putter; David J McLernon; Marinus J Eijkemans; Nan van Geloven
Journal:  Biom J       Date:  2019-11-18       Impact factor: 2.207

3.  Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).

Authors:  Michael B Atkins; Hamzah Abu-Sbeih; Paolo A Ascierto; Michael R Bishop; Daniel S Chen; Madhav Dhodapkar; Leisha A Emens; Marc S Ernstoff; Robert L Ferris; Tim F Greten; James L Gulley; Roy S Herbst; Rachel W Humphrey; James Larkin; Kim A Margolin; Luca Mazzarella; Suresh S Ramalingam; Meredith M Regan; Brian I Rini; Mario Sznol
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

Review 4.  Harnessing repeated measurements of predictor variables for clinical risk prediction: a review of existing methods.

Authors:  Lucy M Bull; Mark Lunt; Glen P Martin; Kimme Hyrich; Jamie C Sergeant
Journal:  Diagn Progn Res       Date:  2020-07-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.